A Phase 2, Open-label Study to Evaluate Safety and Tolerability, and to Explore the Efficacy, of Dosing Regimens of Intraarticular 4975 in Patients With Chronic Moderate to Severe Pain of the Knee Associated With Osteoarthritis

Trial Profile

A Phase 2, Open-label Study to Evaluate Safety and Tolerability, and to Explore the Efficacy, of Dosing Regimens of Intraarticular 4975 in Patients With Chronic Moderate to Severe Pain of the Knee Associated With Osteoarthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Capsaicin (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Anesiva
  • Most Recent Events

    • 26 Sep 2017 According to a Centrexion Therapeutics media release, data will be presented at the 11th Annual Pain and Migraine Therapeutics Summit 2017.
    • 06 May 2009 Actual end date changed from Dec 2008 to Jun 2008 as reported by ClinicalTrials.gov.
    • 03 Mar 2009 Actual number of patients (54) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top